Erasca (NASDAQ: ERAS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-25 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Erasca (NASDAQ: ERAS) through any online brokerage.
Other companies in Erasca’s space includes: Avidity Biosciences (NASDAQ:RNA), TG Therapeutics (NASDAQ:TGTX), Kiniksa Pharmaceuticals (NASDAQ:KNSA), PMV Pharma (NASDAQ:PMVP) and CTI BioPharma (NASDAQ:CTIC).
The latest price target for Erasca (NASDAQ: ERAS) was reported by Evercore ISI Group on Tuesday, August 10, 2021. The analyst firm set a price target for 45.00 expecting ERAS to rise to within 12 months (a possible 673.20% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Erasca (NASDAQ: ERAS) is $5.82 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Erasca.
Erasca’s Q2 earnings are confirmed for Thursday, August 25, 2022.
There is no upcoming split for Erasca.
Erasca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.